Quick Answer
HOOKIPA Pharma Inc. reported Net Income Loss of -$43.50 million for the year ending 2024.
- HOOKIPA Pharma Inc. showed an increase of +46.7% in Net Income Loss from 2023 to 2024.
- This data is from HOOKIPA Pharma Inc.'s annual report (Form 10-K), filed with the SEC on February 28, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$4.57 million | Q2 2018: -$5.82 million | Q3 2018: -$3.95 million | Q4 2018: -$1.89 million | Q1 2019: -$9.33 million | Q2 2019: -$12.08 million | Q3 2019: -$11.39 million | Q4 2019: -$10.24 million | Q1 2020: -$10.93 million | Q2 2020: -$7.09 million | Q3 2020: -$13.59 million | Q4 2020: -$12.48 million | Q1 2021: -$17.24 million | Q2 2021: -$17.15 million | Q3 2021: -$20.04 million | Q1 2022: -$17.97 million | Q2 2022: -$16.36 million | Q3 2022: -$18.28 million | Q1 2023: -$19.68 million | Q2 2023: -$18.02 million | Q3 2023: -$19.07 million | Q1 2024: $14.38 million | Q2 2024: -$19.10 million | Q3 2024: -$13.84 million | Q1 2025: -$15.43 million.
- Over the full 8 years of available data (2017 to 2024), HOOKIPA Pharma Inc.'s Net Income Loss has declined by 241.9%.
- Historical annual values: Fiscal year 2024: -$43.50 million | Fiscal year 2023: -$81.58 million | Fiscal year 2022: -$64.92 million | Fiscal year 2021: -$75.67 million | Fiscal year 2020: -$44.08 million | Fiscal year 2019: -$43.04 million | Fiscal year 2018: -$16.24 million | Fiscal year 2017: -$12.72 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: